Core Viewpoint - Structure Therapeutics Inc. has announced the pricing of its upsized public offering of American depositary shares (ADSs) aimed at raising approximately $650 million to support its development of novel oral small molecule therapeutics for metabolic diseases, particularly obesity [1][2]. Offering Details - The offering consists of 8,461,538 ADSs priced at $65.00 each and pre-funded warrants for 1,538,462 ADSs priced at $64.9999 each [1]. - The gross proceeds from the offering are expected to be around $650 million before deducting underwriting discounts and commissions [2]. - Structure Therapeutics has granted underwriters a 30-day option to purchase an additional 1,500,000 ADSs at the public offering price [2]. Underwriters - Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities, and BMO Capital Markets are acting as joint book-running managers for the offering [3]. Regulatory Information - The offering is made under an automatic shelf registration statement on Form S-3 filed with the SEC on August 6, 2025, which became effective upon filing [4]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available for free on the SEC's website [4]. Company Overview - Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs [6]. - The company utilizes a next-generation structure-based drug discovery platform and has established a robust GPCR-targeted pipeline featuring multiple proprietary clinical-stage oral small molecule compounds [6].